Previous Close | 10.90 |
Open | 10.90 |
Bid | 12.00 |
Ask | 16.50 |
Strike | 115.00 |
Expire Date | 2024-11-15 |
Day's Range | 10.90 - 10.90 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.
The company’s keratoconus medication, Epioxa, was effective in a Phase III trial, with plans to file for submission with the US Food and Drug Administration (FDA).